On April 23, 2026, the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) issued an executive order (the Order)1 to move (i) products approved by the Food and Drug Administration (FDA) containing marijuana and (ii) marijuana products regulated by a state medical marijuana license, from Schedule I of the Controlled Substances Act (CSA) to Schedule III.2 At the time this article was written, only three prescription drugs containing cannabis or cannabis-derived compounds...
